{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:52:38Z","timestamp":1787496758250,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07199-3","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:22:09Z","timestamp":1761214929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["USP21\/YBX1\/HIF1-\u03b1 promotes the progression of prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhuoran","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-3940","authenticated-orcid":false,"given":"Xudong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"7199_CR1","first-page":"14257","volume":"23","author":"S Wasim","year":"2022","unstructured":"Wasim S, Lee S-Y, Kim J. Complexities of prostate cancer. Int J molsci. 2022;23:14257.","journal-title":"Int J molsci"},{"key":"7199_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer JClin. 2025;75:10\u201345.","journal-title":"CA Cancer JClin"},{"key":"7199_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics, 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer JClin. 2021;71:209\u201349.","journal-title":"CA Cancer JClin"},{"key":"7199_CR4","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722.","journal-title":"Lancet"},{"key":"7199_CR5","first-page":"20","volume":"519","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. CancerLett. 2021;519:20\u201329.","journal-title":"CancerLett"},{"key":"7199_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-020-01262-x","volume":"19","author":"T Sun","year":"2020","unstructured":"Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020;19:146.","journal-title":"Mol Cancer"},{"key":"7199_CR7","first-page":"944089","volume":"13","author":"T An","year":"2022","unstructured":"An T, Lu Y, Yan X, Hou J. Insights into the properties, biological functions, and regulation of USP21. FrontPharmacol. 2022;13:944089.","journal-title":"FrontPharmacol"},{"key":"7199_CR8","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41419-022-05163-3","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Chen Z, Tang Q, Wang Z, Lu J, You Y, et al. USP21 promotes self-renewal and tumorigenicity of mesenchymal glioblastoma stem cells by deubiquitinating and stabilizing FOXD1. Cell deathdis. 2022;13:712.","journal-title":"Cell deathdis"},{"key":"7199_CR9","first-page":"681","volume":"10","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zhou B, Chen D. USP21 promotes cell proliferation and metastasis through suppressing EZH2 ubiquitination in bladder carcinoma. Onco targetsther. 2017;10:681\u201389.","journal-title":"Onco targetsther"},{"key":"7199_CR10","first-page":"217064","volume":"597","author":"H Meng","year":"2024","unstructured":"Meng H, Miao H, Zhang Y, Chen T, Yuan L, Wan Y, et al. YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification. CancerLett. 2024;597:217064.","journal-title":"CancerLett"},{"key":"7199_CR11","first-page":"217197","volume":"602","author":"B Li","year":"2024","unstructured":"Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, et al. YBX1 as a therapeutic target to suppress the LRP1-\u03b2-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. CancerLett. 2024;602:217197.","journal-title":"CancerLett"},{"key":"7199_CR12","doi-asserted-by":"publisher","first-page":"e2215132120","DOI":"10.1073\/pnas.2215132120","volume":"120","author":"S Chen","year":"2023","unstructured":"Chen S, Li K, Guo J, Chen H-N, Ming Y, Jin Y, et al. circNEIL3 inhibits tumor metastasis through recruiting the E3 ubiquitin ligase Nedd4L to degrade YBX1. Proc Natl Acad sciu S A. 2023;120:e2215132120.","journal-title":"Proc Natl Acad sciu S A"},{"key":"7199_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2020009676","volume":"138","author":"M Feng","year":"2021","unstructured":"Feng M, Xie X, Han G, Zhang T, Li Y, Li Y, et al. YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021;138:71\u201385.","journal-title":"Blood"},{"key":"7199_CR14","first-page":"323","volume":"112","author":"M Shiota","year":"2021","unstructured":"Shiota M, Sekino Y, Tsukahara S, Abe T, Kinoshita F, Imada K, et al. Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression. CancerSci. 2021;112:323\u201330.","journal-title":"CancerSci"},{"key":"7199_CR15","first-page":"66","volume":"490","author":"M Bates","year":"2020","unstructured":"Bates M, Boland A, McDermott N, Marignol L. YB-1: the key to personalised prostate cancer management? CancerLett. 2020;490:66\u201375.","journal-title":"CancerLett"},{"key":"7199_CR16","first-page":"101","volume":"29","author":"S Peng","year":"2024","unstructured":"Peng S, Guo Y, Irondelle M, Mazzu A, Kahi M, Ferreira Montenegro P, et al. The marine-derived HIF-1\u03b1 inhibitor, Yardenone 2, reduces prostate cancer cell proliferation by targeting HIF-1 target genes. Cell Mol BiolLett. 2024;29:101.","journal-title":"Cell Mol BiolLett"},{"key":"7199_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ccell.2015.04.003","volume":"27","author":"AM El-Naggar","year":"2015","unstructured":"El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TGP, Negri GL, Somasekharan SP, et al. Translational activation of HIF1\u03b1 by YB-1 promotes sarcoma metastasis. Cancer Cell. 2015;27:682\u201397.","journal-title":"Cancer Cell"},{"key":"7199_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/cyto.a.20896","volume":"77A","author":"J Adler","year":"2010","unstructured":"Adler J, Parmryd I. Quantifying colocalization by correlation: the Pearson correlation coefficient is superior to the Mander\u2019s overlap coefficient. Cytometry Part A. 2010;77A:733\u201342.","journal-title":"Cytometry Part A"},{"key":"7199_CR19","doi-asserted-by":"publisher","first-page":"C723","DOI":"10.1152\/ajpcell.00462.2010","volume":"300","author":"KW Dunn","year":"2011","unstructured":"Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am J Physiol cellphysiol. 2011;300:C723\u2013742.","journal-title":"Am J Physiol cellphysiol"},{"key":"7199_CR20","doi-asserted-by":"publisher","first-page":"0252","DOI":"10.34133\/research.0252","volume":"6","author":"H Wang","year":"2023","unstructured":"Wang H, Liu J, Zhu X, Yang B, He Z, Yao X. AZGP1P2\/UBA1\/RBM15 cascade mediates the fate determinations of prostate cancer stem cells and promotes therapeutic effect of docetaxel in castration-resistant prostate cancer via TPM1 m6A modification. Research. 2023;6:0252.","journal-title":"Research"},{"key":"7199_CR21","first-page":"3431","volume":"66","author":"F G\u00f6ricke","year":"2023","unstructured":"G\u00f6ricke F, Vu V, Smith L, Scheib U, B\u00f6hm R, Akkilic N, et al. Discovery and characterization of BAY-805, a potent and selective inhibitor of ubiquitin-specific protease USP21. J MedChem. 2023;66:3431\u201347.","journal-title":"J MedChem"},{"key":"7199_CR22","first-page":"96","volume":"177","author":"M He","year":"2017","unstructured":"He M, Zhou Z, Wu G, Chen Q, Wan Y. Emerging role of DUBs in tumor metastasis and apoptosis: therapeutic implication. PharmacolTher. 2017;177:96\u2013107.","journal-title":"PharmacolTher"},{"key":"7199_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"7199_CR24","first-page":"1389","volume":"13","author":"CAM Semple","year":"2003","unstructured":"Semple CAM, Group RG, Members GSL. The comparative proteomics of ubiquitination in mouse. GenomeRes. 2003;13:1389\u201394.","journal-title":"GenomeRes"},{"key":"7199_CR25","first-page":"702","volume":"32","author":"G Wang","year":"2025","unstructured":"Wang G, Dai S, Chen J, Zhang K, Huang C, Zhang J, et al. USP19 potentiates autophagic cell death via inhibiting mTOR pathway through deubiquitinating NEK9 in pancreatic cancer. Cell deathdiffer. 2025;32:702\u201313.","journal-title":"Cell deathdiffer"},{"key":"7199_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12943-023-01892-x","volume":"22","author":"J Kwon","year":"2023","unstructured":"Kwon J, Zhang J, Mok B, Allsup S, Kim C, Toretsky J, et al. USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity. Mol Cancer. 2023;22:204.","journal-title":"Mol Cancer"},{"key":"7199_CR27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1101\/gad.339804.120","volume":"34","author":"W Li","year":"2020","unstructured":"Li W, Shen M, Jiang Y-Z, Zhang R, Zheng H, Wei Y, et al. Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. GenesDev. 2020;34:1310\u201315.","journal-title":"GenesDev"},{"key":"7199_CR28","first-page":"59","volume":"40","author":"J Ge","year":"2021","unstructured":"Ge J, Yu W, Li J, Ma H, Wang P, Zhou Y, et al. USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-myc. J Exp Clin cancerres. 2021;40:59.","journal-title":"J Exp Clin cancerres"},{"key":"7199_CR29","doi-asserted-by":"publisher","first-page":"e14799","DOI":"10.7717\/peerj.14799","volume":"11","author":"Y Guo","year":"2023","unstructured":"Guo Y, Cui S, Chen Y, Guo S, Chen D. Ubiquitin specific peptidases and prostate cancer. PeerJ. 2023;11:e14799.","journal-title":"PeerJ"},{"key":"7199_CR30","first-page":"3292","volume":"41","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wang J, Luan T, Zuo Y, Chen J, Zhang H, et al. Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics. OncolRep. 2019;41:3292\u2013304.","journal-title":"OncolRep"},{"key":"7199_CR31","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1101\/gad.326314.119","volume":"33","author":"P Hou","year":"2019","unstructured":"Hou P, Ma X, Zhang Q, Wu C-J, Liao W, Li J, et al. USP21 deubiquitinase promotes pancreas cancer cell stemness via wnt pathway activation. GenesDev. 2019;33:1361\u201366.","journal-title":"GenesDev"},{"key":"7199_CR32","doi-asserted-by":"publisher","first-page":"64095","DOI":"10.18632\/oncotarget.19322","volume":"8","author":"HT Nguyen","year":"2017","unstructured":"Nguyen HT, Kugler J-M, Loya AC, Cohen SM. USP21 regulates Hippo pathway activity by mediating MARK protein turnover. Oncotarget. 2017;8:64095\u2013105.","journal-title":"Oncotarget"},{"key":"7199_CR33","first-page":"21701","volume":"14","author":"Y Murakami","year":"2024","unstructured":"Murakami Y, Katsuchi D, Matsumoto T, Kanazawa K, Shibata T, Kawahara A, et al. Y-box binding protein 1\/cyclin A1 axis specifically promotes cell cycle progression at G2\/M phase in ovarian cancer. SciRep. 2024;14:21701.","journal-title":"SciRep"},{"key":"7199_CR34","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.21037\/tcr-21-2087","volume":"10","author":"J Zhao","year":"2021","unstructured":"Zhao J, Zhang P, Wang X. YBX1 promotes tumor progression via the PI3K\/AKT signaling pathway in laryngeal squamous cell carcinoma. Transl cancerres. 2021;10:4859\u201369.","journal-title":"Transl cancerres"},{"key":"7199_CR35","doi-asserted-by":"crossref","unstructured":"Shiota M, Fujimoto N, Imada K, Yokomizo A, Itsumi M, Takeuchi A, et al. Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7. J Natl Cancer Inst. 2016;108(4):djv351.","DOI":"10.1093\/jnci\/djw005"},{"key":"7199_CR36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-11-0017","volume":"18","author":"M Shiota","year":"2011","unstructured":"Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, et al. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer. 2011;18:505\u201317.","journal-title":"Endocr Relat Cancer"},{"key":"7199_CR37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/cancers12030660","volume":"12","author":"K Nikhil","year":"2020","unstructured":"Nikhil K, Raza A, Haymour HS, Flueckiger BV, Chu J, Shah K. Aurora kinase A-YBX1 synergy fuels aggressive oncogenic phenotypes and chemoresistance in castration-resistant prostate cancer. Cancers (basel). 2020;12:660.","journal-title":"Cancers (basel)"},{"key":"7199_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","volume":"23","author":"F Liu","year":"2024","unstructured":"Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, et al. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol Cancer. 2024;23:148.","journal-title":"Mol Cancer"},{"key":"7199_CR39","first-page":"882372","volume":"12","author":"S-P Chen","year":"2022","unstructured":"Chen S-P, Zhu G-Q, Xing X-X, Wan J-L, Cai J-L, Du J-X, et al. LncRNA USP2-AS1 promotes hepatocellular carcinoma growth by enhancing YBX1-mediated HIF1\u03b1 protein translation under Hypoxia. FrontOncol. 2022;12:882372.","journal-title":"FrontOncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07199-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:22:12Z","timestamp":1761214932000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07199-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7199"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07199-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Shanghai Tenth People\u2019s Hospital (No. SHSY-IEC-5.0\/19K110\/P01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"There is no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1164"}}